-- 周四下午，科技股涨跌互现，道富科技精选行业SPDR ETF (XLK)下跌0.4%，道富SPDR标普半导体ETF (XSD)上涨3.7%。 费城半导体指数上涨1.6%。 行业新闻方面，据彭博社报道，Anthropic正在考虑新一轮融资，公司估值可能超过9000亿美元，有望超越OpenAI，成为全球最有价值的人工智能初创公司。 公司新闻方面，Meta Platforms (META)股价下跌超过9%，此前该公司隔夜上调了2026年资本支出预期，抵消了其第一季度盈利和营收超出预期的利好消息。 Alphabet (GOOGL)股价上涨9.5%，此前该公司隔夜公布的第一季度盈利和营收均超出市场预期。 微软 (MSFT)周三晚间公布的第三财季调整后每股收益为4.27美元，高于去年同期的3.54美元。 FactSet调查的分析师预期每股收益为4.05美元。该公司股价下跌超过5%。
Related Articles
Sectors
Sector Update: Financial
Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.
$AVB$EQR
Australia
Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid
Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%
$AAPL$META
Australia
Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation
Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%
$AXSM